Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Regeneron Pharmaceuticals Inc

REGN
666,87
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 11:41:43
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/3/202503:50PRNUSRegeneron Science Talent Search 2025 Awards More Than $1.8..
12/3/202502:32GLOBERegeneron Science Talent Search 2025 Awards More Than $1.8..
10/3/202510:45PRNUSREGN LAWSUIT ALERT: The Gross Law Firm Notifies Regeneron..
08/3/202519:00GLOBEDupixent® (dupilumab) Late-Breaking Positive Pivotal Data in..
06/3/202511:45PRNUSRegeneron Pharmaceuticals, Inc. Class Action: The Gross Law..
03/3/202511:45PRNUSShareholders of Regeneron Pharmaceuticals, Inc. Should..
28/2/202513:00GLOBELinvoseltamab Recommended for EU Approval by the CHMP to..
27/2/202511:45PRNUSShareholders that lost money on Regeneron Pharmaceuticals,..
26/2/202513:00GLOBEOdronextamab BLA Accepted for FDA Review for the Treatment..
24/2/202521:00GLOBELatest DB-OTO Results Demonstrate Clinically Meaningful..
24/2/202511:45PRNUSShareholders that lost money on Regeneron Pharmaceuticals,..
20/2/202511:45PRNUSRegeneron Pharmaceuticals, Inc. Sued for Securities Law..
18/2/202506:59GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
13/2/202511:45PRNUSThe Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc...
11/2/202522:05GLOBERegeneron Announces Investor Conference Presentations
11/2/202513:00GLOBELinvoseltamab BLA Accepted for FDA Review for the Treatment..
10/2/202511:45PRNUSThe Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc...
08/2/202523:40GLOBEEYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3..
08/2/202521:55GLOBEThree-Year Results for EYLEA HD® (aflibercept) Injection 8..
07/2/202522:36EDGAR2Form 13F-HR - Quarterly report filed by institutional..
06/2/202511:45PRNUSClass Action Filed Against Regeneron Pharmaceuticals, Inc...
05/2/202515:18EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
04/2/202513:11EDGAR2Form 8-K - Current report
04/2/202512:30GLOBERegeneron Reports Fourth Quarter and Full Year 2024..
03/2/202511:45PRNUSShareholders of Regeneron Pharmaceuticals, Inc. Should..
30/1/202511:45PRNUSThe Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc...
27/1/202511:45PRNUSContact The Gross Law Firm by March 10, 2025 Deadline to..
23/1/202518:02PRNUSAmerica's Top 40 High School Scientists to Compete for $1.8..
23/1/202518:00GLOBEAmerica’s Top 40 High School Scientists to Compete for $1.8..
23/1/202511:45PRNUSLost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join..
21/1/202520:35PRNCAREGENERON RENFORCE SA PRÉSENCE AU CANADA EN OUVRANT SON..
20/1/202511:45PRNUSRegeneron Pharmaceuticals, Inc. Class Action: The Gross Law..
16/1/202511:45PRNUSThe Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc...
13/1/202512:30GLOBERegeneron Provides Business Updates and Highlights from..
13/1/202512:15GLOBEAdjuvant Libtayo® (cemiplimab) Significantly Improves..
13/1/202512:05GLOBERegeneron Collaborates with Truveta and Leading American..
13/1/202511:45PRNUSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff..
07/1/202522:05GLOBERegeneron to Report Fourth Quarter and Full Year 2024..
06/1/202523:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202413:00GLOBERegeneron to Advance Two Factor XI Antibodies into a Broad..
18/12/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 666,87

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network